Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems
Vaccines,
Год журнала:
2024,
Номер
12(8), С. 873 - 873
Опубликована: Авг. 1, 2024
mRNA
vaccines
are
leading
a
medical
revolution.
technologies
utilize
the
host's
own
cells
as
bio-factories
to
produce
proteins
that
serve
antigens.
This
revolutionary
approach
circumvents
complicated
processes
involved
in
traditional
vaccine
production
and
empowers
with
ability
respond
emerging
or
mutated
infectious
diseases
rapidly.
Additionally,
robust
cellular
immune
response
elicited
by
has
shown
significant
promise
cancer
treatment.
However,
inherent
instability
of
complexity
tumor
immunity
have
limited
its
broader
application.
Although
emergence
pseudouridine
ionizable
cationic
lipid
nanoparticles
(LNPs)
made
clinical
application
possible,
there
remains
substantial
potential
for
further
improvement
immunogenicity
delivered
antigens
preventive
therapeutic
effects
technology.
Here,
we
review
latest
advancements
vaccines,
including
but
not
target
selection
delivery
systems.
offers
multifaceted
perspective
on
this
rapidly
evolving
field.
Язык: Английский
Recent Advances in the Development and Efficacy of Anti-Cancer Vaccines—A Narrative Review
Vaccines,
Год журнала:
2025,
Номер
13(3), С. 237 - 237
Опубликована: Фев. 25, 2025
Immunotherapy
is
an
established
and
efficient
treatment
strategy
for
a
variety
of
malignancies.
It
aims
to
boost
the
anticancer
properties
one’s
own
immune
system.
Several
immunotherapeutic
options
are
available,
but
checkpoint
blockers
represent
most
widely
known
investigated.
Anticancer
vaccines
evolving
area
immunotherapy
that
stimulate
antigen-presenting
cells,
cytotoxic
responses
CD8+
T
presence
memory
among
others.
Over
years,
different
approaches
have
been
studied,
such
as
mRNA
DNA
vaccines,
together
with
dendritic
cell-
viral
vector-based
vaccines.
Recently,
accumulating
number
clinical
studies
performed
analyze
safety
potential
efficacy
these
agents.
The
aim
this
review
summarize
recent
advances
regarding
types
therapeutic
Furthermore,
it
will
discuss
how
in
preclinical
models
can
enhance
outcomes.
Язык: Английский
The use of peptides for deciphering the mechanism of EBV, HPV, and HCV invasion of human cells
Опубликована: Март 26, 2025
Epstein-Barr
virus
(EBV),
human
papillomavirus
(HPV),
and
hepatitis
C
(HCV)
are
significant
pathogens
associated
with
various
diseases,
employing
complex
molecular
mechanisms
for
cellular
entry
immune
evasion.
Peptide-based
research,
using
more
than
700
synthetic
peptides,
has
deciphered
some
of
the
interactions
between
viral
proteins
host
cell
receptors,
offering
promising
diagnostics
therapeutic
strategies.
In
EBV,
binding
peptides
have
been
identified:
11382,
11389,
11416
derived
from
gp350/220;
11435,
11436,
11438
gp85
[glycoprotein
H
(gH)];
11521
BNRF1/p140.
Most
these
peptide
sequences
surface-exposed
part
contact
regions
making
them
candidates
strategies
aimed
at
inhibiting
EBV
invasion
cells.
Peptide
11382
is
target
neutralizing
antibody
72A1;
induce
interleukin-6
production;
11435
binds
to
integrin
αvβ6,
triggers
a
cytokine
storm.
HPV
L1
protein,
major
component
capsid,
18283
18294
identified
as
epithelial
cell-binding
located
on
surface.
Parts
recognized
by
anti-HPV
antibodies.
These
two
along
18301,
potential
biomarkers
infection
because
they
antibodies
elicited
during
natural
infection,
suitable
targets
serological
detection.
envelope
E1
E2
HCV,
five
hepatocyte-
CD81-positive
identified.
The
contain
linear
B-cell
epitopes
antibodies,
used
develop
tests
determining
HCV
infection.
approaches
can
lead
innovative
prevention,
diagnosis,
treatment
diseases.
Additionally,
their
be
modulate
response
generate
tools
cancer
theragnostic.
Язык: Английский
Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response
Journal for ImmunoTherapy of Cancer,
Год журнала:
2024,
Номер
12(11), С. e010251 - e010251
Опубликована: Ноя. 1, 2024
For
best
efficacy,
vaccines
must
provide
long-lasting
immunity.
To
measure
longevity,
memory
from
B
and
T
cells
are
surrogate
endpoints
for
vaccine
efficacy.
When
antibodies
insufficient
protection,
the
immune
response
rely
on
cells.
The
magnitude
differentiation
of
effective,
durable
responses
depend
antigen-specific
precursor
frequencies.
However,
development
that
induce
T-cell
cancer
treatment
has
remained
elusive.
Язык: Английский
A Preclinical Immunogenicity Study of the Recombinant Human Papillomavirus Nine-Valent Virus-like Particle Vaccine
Dan Xu,
Jiadai Li,
Jiao An
и другие.
Vaccines,
Год журнала:
2024,
Номер
12(12), С. 1356 - 1356
Опубликована: Ноя. 30, 2024
Background:
Cervical
cancer
is
associated
with
persistent
infection
of
high-risk
human
papillomaviruses
(HPVs).
Prophylactic
HPV
vaccines
have
been
recommended
and
significant
efficacy
in
preventing
cervical
cancer.
Multivalent
a
better
preventative
effect
on
HPV-related
diseases.
However,
there
currently
only
one
nine-valent
vaccine
the
market:
Gardasil®
9.
The
development
new
still
urgent
order
to
achieve
goal
eliminating
as
proposed
by
WHO.
Methods:
In
this
study,
we
developed
recombinant
virus-like
particle
(VLP)
(HPV-9
vaccine)
containing
type
6,
11,
16,
18,
31,
33,
45,
52,
58
antigens,
an
adjuvant
aluminum
phosphate
(AlPO4).
type-specific
L1
proteins
were
recombinantly
expressed
using
Pichia
pastoris,
followed
self-assembly
into
VLPs.
Immunogenicity
studies
HPV-9
performed
rodents
(mice
rats)
non-human
primates
(macaques)
animal
models.
Results:
showed
that
able
elicit
robust
long-lasting
neutralizing
antibody
response
(cynomolgus
macaque)
shows
immunogenicity
comparable
Walrinvax®
Conclusions:
summary,
study
provides
comprehensive
investigation
vaccine,
including
its
immune
persistence.
These
findings,
derived
from
models
diverse
species,
contribute
valuable
insights
potential
candidate
clinical
settings.
Язык: Английский